Q-omics provides the consensus-scored KLHDC7B profile across patient tissues and cancer cell-line models. KLHDC7B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KLHDC7B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KLHDC7B RNA expression shows 13,533 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where KLHDC7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHDC7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHDC7B survival associations across molecular data types. KLHDC7B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHDC7B RNA expression–survival associations across cancer types. High KLHDC7B expression shows unfavorable associations in KIRC and LGG, but favorable associations in SKCM, HNSC, SCLC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KLHDC7B RNA expression.
This table summarizes KLHDC7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLHDC7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHDC7B shows higher tumor expression in HNSC, THCA, BLCA, LUAD, LIHC and STAD. The HNSC box plot shows higher KLHDC7B RNA expression in tumor versus normal tissue (log2 FC = +2.654, t-test p < 0.001).
This table shows molecular features associated with KLHDC7B in patient tissues and cancer cell lines. In patient samples, KLHDC7B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHDC7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
